The 2010 Affordable Care Act created a shorter licensing path for lower-cost versions of cell-derived drugs called biologics. Sarfaraz Niazi is working to get among the first of these substitute drugs called biosimilars approved by the U.S. Food and Drug Administration. A former Abbott Labs scientist and University of Illinois at Chicago professor, Niazi is founder, chairman and CEO of Therapeutic Proteins International LLC in Chicago. He shares how he’s taking the cost out of manufacturing biological drugs and provides advice on being a better inventor.
Therapeutic Protein’s CEO, Sarfaraz K. Niazi
Read the interview on BlueSky Innovation